deltatrials
Terminated PHASE3 INTERVENTIONAL 1-arm NCT02456103

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Sponsor: PTC Therapeutics

Conditions Cystic Fibrosis
Interventions Ataluren
Updated 14 times since 2017 Last updated: Apr 14, 2020 Started: Aug 31, 2015 Primary completion: Jun 2, 2017 Completion: Jun 2, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Cystic Fibrosis (CF) data from the double-blind CF Study PTC124-GD-021-CF did not meet endpoints.

Other terminated trials from PTC Therapeutics

See all terminations from PTC Therapeutics

Other Cystic Fibrosis trials with similar outcome

Browse all Cystic Fibrosis trials

This PHASE3 trial investigates Cystic Fibrosis and is currently terminated or withdrawn. PTC Therapeutics leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~May 2020 · 15 months · monthly snapshot~May 2020 – ~Nov 2020 · 6 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

▶ Show 9 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE3

  2. May 2020 — Nov 2020 [monthly]

    Terminated PHASE3

  3. Feb 2019 — May 2020 [monthly]

    Terminated PHASE3

  4. Jan 2019 — Feb 2019 [monthly]

    Terminated PHASE3

  5. Jun 2018 — Jan 2019 [monthly]

    Terminated PHASE3

  6. Oct 2017 — Jun 2018 [monthly]

    Terminated PHASE3

  7. Jun 2017 — Oct 2017 [monthly]

    Terminated PHASE3

    Status: Enrolling By Invitation → Terminated

  8. Feb 2017 — Jun 2017 [monthly]

    Enrolling By Invitation PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Enrolling By Invitation PHASE3

    First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • PTC Therapeutics
Data source: PTC Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ancona, Italy , Aurora, United States , Barcelona, Spain , Berlin, Germany , Birmingham, United States , Bochum, Germany , Boston, United States , Brussels, Belgium , Buenos Aires, Argentina and 53 more locations